Meeting
2019 Gastrointestinal Cancers Symposium
Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.
Authors
Zev A. Wainberg
University of California Los Angeles School of Medicine, Los Angeles, CA
Zev A. Wainberg , Kynan Feeney , Myung Ah Lee , Andres J. Muñoz Martín , Antonio Cubillo Gracián , Sara Lonardi , Baek-Yeol Ryoo , Annie Hung , Yong Lin , Johanna C. Bendell , J. Randolph Hecht
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 202)
DOI
10.1200/JCO.2019.37.4_suppl.202
Abstract #
202
Poster Bd #
A18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).
First Author: Linde Kehmann
Poster
2014 ASCO Annual Meeting
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
First Author: Thomas Adam Abrams
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz